H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Keros Therapeutics (KROS) to $25 from $40 and keeps a Buy rating on the shares. Th firm says the early termination of the TROPOS trial due to pericardial effusions across all dose cohorts “was a clear setback for cibotercept.” However, the forthcoming dataset still matters, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics: Buy Rating Affirmed Amid Promising Trial Data and Strategic Initiatives
- Keros Therapeutics Reports Strong Q1 2025 Results
- Keros Therapeutics: Promising Developments Amidst Uncertainties Lead to Hold Rating
- Keros Therapeutics reports Q1 EPS $3.62
- Strategic Opportunities and Partnerships Highlight Keros Therapeutics’ Potential: A Buy Recommendation by Jason Zemansky
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue